Skip to main content
Premium Trial:

Request an Annual Quote

Profos Raises $6.1M to Develop, Market Bacterial Detection Based on Phage Ligand Technology

NEW YORK, Aug. 24 (GenomeWeb News) - Profos of Regensburg, Germany, has raised €5 million ($6.1 million) in venture capital to develop and market new products for the capture and detection of bacteria and endotoxins, the company said yesterday.


Profos has been developing its phage-ligand technology for two applications in pathogen testing for food safety and for the detection and removal of bacterial endotoxins during the manufacture of biopharmaceutical drugs.


The funding came from lead investor Bio Fund Management of Helsinki, Finland, and from two existing shareholders, Danisco Venture of Copenhagen, Denmark, and Capital Stage of Hamburg, Germany.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.